Development of transformative therapies for the treatment of worsening and acute decompensated heart failure

Omnes Capital

Invivo Capital Partners

Kurma Partners

V-Bio Ventures

Corteria Pharmaceuticals

CrUX Dataset

Person Schema

CrUX Top 50m

Gravatar Profiles

Chief Medical Officer

Francesca Lawson

Claire Poulard

Ward Capoen

Peter Neubeck

Lluis Pareras

Thierry Laugel

Philip Janiak

Founder & CEO

Marie-Laure Ozoux

Founder & Chief Scientific Officer

Regis Olivier

Therapeutics Companies (Top 10K)

Pharmaceutical Companies With Fewer Than 100 Employees (Top 10K)

Startups with Female Founders (Top 10K)

Europe Companies With Less Than $500M in Revenue (Top 10K)

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.

Jeito Capital

OrbiMed

Series A - Corteria Pharmaceuticals

Seed Round - Corteria Pharmaceuticals

Paris

Ile-de-France

France

Europe

Corteria appoints Mark Pruzanski as chairman

Pharma is focusing on the heart of the problem

Levées de fonds : La French Tech face au défi de la crise du financement

MaddyMoney : 1,78 milliard d'euros levés pendant le mois de ...

Deux cabinets sur le financement de Corteria Pharmaceuticals

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in ...

MindMaze is a competitor of Corteria Neurotechnologies, offering treatments for neurological diseases.

MindMaze

Nexstim is a competitor of Corteria Neurotechnologies, specializing in treatments for neurological disorders.

Nexstim

Johnson & Johnson Services, Inc. offers treatments for multiple sclerosis, Parkinson's disease, and migraine, making it a competitor of Corteria Pharma.

Johnson & Johnson Services, Inc.

Arrakis Therapeutics is a competitor of Corteria Pharmaceuticals, focusing on developing therapeutics for neurological diseases.

Arrakis Therapeutics

MyoKardia is a competitor of Corteria Pharmaceuticals, involved in the development of therapies for cardiovascular and neurological diseases.

MyoKardia

Corteria Pharma is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological diseases. The company's lead product candidate is targeting Multiple Sclerosis (MS) with a potential best-in-class profile.

Corteria Pharma

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 16, 2024 8:54 AM	29d3e1b9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:50 PM	b7e39818
crunchbase profile	general	Oct 29, 2024 8:24 AM	76ba8f26
li profile	general	May 16, 2024 8:54 AM	27fae51d
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	c25791dc
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CORTERIAPHARMA

Corteria Pharma